The global biomaterials market size was estimated at USD 135.4 billion in 2021 and is expected to register a compound annual growth rate (CAGR) of 15.4% from 2022 to 2030. The rising prevalence of musculoskeletal and chronic skeletal medical conditions is expected to boost the demand for biomaterial-based implants, thereby augmenting the market growth. The demand fororthopedic implantsis also rising owing to the increasing geriatric population, at an increased risk of osteoarthritis, osteoporosis, and other musculoskeletal disorders. The development of various biomaterial and biomedical devices is in demand for detecting and treating coronavirus. In this pandemic, early detection of the virus is very crucial to limit the transmission of the same. The infection from the COVID-19 can be detected using existing biomedical devices which are based on eitherPolymerase Chain Reaction(PCR) or Non-PCR methods.
Biomaterial Technologies contribute to the development of new efficient personal protective equipment, drug deliveries, vaccines, and new therapeutics which are used to prevent or treat the infection from SARS-COV-2. Furthermore, cell-cultured models and engineered tissues had a major impact on investigating the infection, testing, and developing vaccines and therapeutics. Thus, the market resulted in varied designs of a range of diagnosis and therapeutic tools for the management of COVID-19, which includes rapid and accurate diagnostic platforms, novel vaccines, effective anti-viral drugs, and efficient models of laboratories for accessing the disease. Technological advancements have made biomaterials more versatile and have increased their utility in various fields of healthcare, such as bioengineering andtissue engineering.
The advent of smart biomaterials that interact with biological systems for several biomedical applications, ranging from the transport of bioactive molecules to the cellular functioning of the engineered functional tissues, drives revenue generation in this market. Companies are embracing the ongoing developments in novel drug delivery approaches for the controlled release of drugs, thus fueling market growth. For instance, in January 2019, DSM Biomedical partnered with ProMed Pharma to leverage its biomedical biomaterials with ProMed’s micro molding and extrusion capabilities to create novel controlled-release drug implants and combination devices.
The porous-coated and fully or partially porous orthopedic implants have gained immense popularity in recent years. This is because the porous structures reduce the elastic modulus and stimulate bone growth around the implant.Powder metallurgy,3-D printing, andadditive manufacturingare some of the potential techniques to manufacture porous metallic and ceramic implants. Growing demand for smart biomaterials that produce and transfer bioelectric signals similar to native tissues for accurate physiological functions, is expected to surge the market growth. Piezoelectric scaffolds are smart materials that play a significant role in tissue engineering. They stimulate the signaling pathways and consequently improve tissue regeneration at the impaired site.
The polymer product segment dominated the market in terms of revenue at a share of 28.2% in 2021 and is expected to continue leading throughout the forecast period owing to the wide range of product applications. The wide availability of biopolymers and advanced polymers for bio-resorbable tissue fixation and other orthopedic applications is also expected to accelerate the revenue generation of the segment. Polymeric biomaterials are one of the cornerstones of tissue engineering. Ongoing progression in technologies, such as micro-manufacturing, surface modification, drug delivery, nanotechnology, and high-throughput screening, play an integral role in broadening the polymeric material usage in the tissue engineering field.
Natural biomaterials are anticipated to witness a lucrative growth rate during the forecast period, owing to various benefits of the product over synthetic biomaterials in terms of biodegradability, biocompatibility, and remodeling. Due to these advantages, they are increasingly used to replace or restore the structure and function of damaged organs or tissues. ABiosensor是一种分析装置,用于检测安娜吗lytes such as biomolecules or biological elements of species produced by micro-organisms, that is, tissues, enzymes, organelles, etc. The sensor mainly consists of three parts that are, a bio-receptor (enzymes, antibodies, nucleic acids), a transducer (electrochemical, electrical, optical, thermal, magnetic resonance), and an electronic system that comprises a signal amplifier.
The orthopedic application segment dominated the market in terms of revenue at a share of 23.0% in 2021. Increasing adoption of metallic biomaterials in orthopedic applications due to their high load-bearing capacity is one of the factors driving the segment growth. Besides, continuous developments for the introduction of advanced orthopedic implants by market vendors are also expected to propel revenue generation. For instance, in November 2019, DiFusion Inc. received FDA approval for its Xiphos-ZF spinal interbody device, which is based on a different biomaterial Zfuze, a combination of poly-ether-ether-ketone and titanium. This new biomaterial leads to significant reductions of cytokine markers that cause inflammation and are associated with fibrous tissue formation.
The plastic surgery application segment is expected to grow at a significant pace in the coming years owing to the increasing number of cosmetic procedures and increased usage of biomaterials in these surgeries. As per the 2019 publication of the International Society of Aesthetic Plastic Surgery, in the U.S., around 4.3 million cosmetic procedures were performed in 2018, which has positively influenced segment growth.
North America dominated the market and accounted for the largest revenue share of 38.2% in 2021 owing to the initiatives undertaken by various public and private organizations. These include the National Science Foundation and the National Institute of Standards and Technology, which provide knowledge and assistance pertaining to biomaterials usage in biomedical applications. This has resulted in the expansion of biomaterials adoption in this region. Moreover, factors such as favorable government policies and the presence of several major market players in this region have contributed to the regional market share.
In Asia Pacific, the market is expected to register the highest CAGR over the forecast period, owing to strategic initiatives adopted by the regional participants to reinforce their presence in local as well as global markets. For instance, in November 2019, a Japan-based company, Mitsubishi Chemical signed an agreement with U.S.-based AdvanSource Biomaterials to acquire their thermoplastic polyurethane elastomer business. This acquisition is expected to help the company expand its business footprint globally and capture a significant share in the international market. In India, the biomaterials market is constantly booming. The Indian biomaterials industry is dominated by orthopedic, dental, and cardiovascular biomaterials. Increasing market shares of cardiovascular and orthopedic and biomaterial products are due to an increase in orthopedic surgery, cardiovascular surgeries, and dental procedures.
Key companies are making significant investments to expand their presence and maintain a competitive edge. They are also adopting strategies such as agreements, partnerships, and collaboration models to strengthen their product portfolio. Moreover, key vendors are inclined toward the development of more innovative products to expand their biomaterials offerings. For instance, in March 2022, Evonik Industries commercially launched EUDRATEC Fasteric used for enteric fortification and prompt release in the upper smaller intestine, which is a platform of oral drug delivery technology directly over the released target. This product development improved the biocompatibility, safety, and performance of implantable products used by medical device customers and further strengthened Evonik’s growth. In April 2022, Medtronic and GE Healthcare announced a partnership to address the specific needs and demand for treatment in ambulatory surgery centers (ASCs) and office-based laboratories (OBLs). Customers will have access to a comprehensive product portfolio, financial solutions, and great support as a result of this new partnership. Some of the prominent players in the biomaterials market include:
Medtronic plc
Evonik Industries AG
Carpenter Technology Corporation
Berkeley Advanced Biomaterials
Invibio Ltd.
Zimmer Biomet Holdings, Inc.
BASF SE
Covalon Technologies Ltd.
Stryker
Johnson & Johnson
Dentsply Sirona
CoorsTek Inc.
Corbion
Collagen Matrix, Inc.
Report Attribute |
Details |
Market size value in 2022 |
USD 155.0 billion |
Revenue forecast in 2030 |
USD 488.7 billion |
Growth Rate |
CAGR of 15.4% from 2022 to 2030 |
Base year for estimation |
2021 |
Historical data |
2018 - 2020 |
Forecast period |
2022 - 2030 |
Quantitative units |
Revenue in USD million and CAGR from 2022 to 2030 |
Report coverage |
Revenue forecast; company share; competitive landscape; growth factors and trends |
Segments covered |
Product, application, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; Germany; U.K.; Japan; China; Brazil; Mexico; South Africa |
Key companies profiled |
Medtronic plc; Evonik Industries AG; Carpenter Technology Corporation; Berkeley Advanced Biomaterials; Invibio Ltd.; Zimmer Biomet Holdings, Inc.; BASF SE; Covalon Technologies Ltd.; Stryker; Johnson & Johnson; Dentsply Sirona; CoorsTek Inc.; Corbion; Collagen Matrix, Inc. |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country; regional and segment scope |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs.Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global biomaterials market report on the basis of product, application, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Metallic
Natural
Ceramics
Polymers
Application Outlook (Revenue, USD Million, 2018 - 2030)
Cardiovascular
Sensors
Stents
Guidewires
Implantable Cardiac Defibrillators
Pacemakers
Vascular Grafts
Others
Ophthalmology
Synthetic Corneas
Intraocular Lens
Contact Lens
Ocular Tissue Replacement
Others
Dental
Tissue Regeneration Materials
Dental Implants
Bone Grafts & Substitutes
Dental Membranes
Others
Orthopedic
Joint Replacement Biomaterials
Orthobiologics
Bioresorbable Tissue Fixation Products
Viscosupplementation
Spine Biomaterials
Others
Wound Healing
Fracture Healing Device
Adhesion Barrier
Skin Substitutes
Internal Tissue Sealant
Surgical Hemostats
Others
Tissue Engineering
Plastic Surgery
Facial Wrinkle Treatment
Soft Tissue Fillers
Craniofacial Surgery
Bioengineered Skins
Peripheral Nerve Repair
Acellular Dermal Matrices
Others
Neurology
Neural Stem Cell Encapsulation
Shunting Systems
Hydrogel Scaffold For CNS Repair
Cortical Neural Prosthetics
Others
Others
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
U.K.
Asia Pacific
Japan
China
Latin America
Brazil
Mexico
Middle East and Africa (MEA)
South Africa
b.The global biomaterials market size was estimated at USD 135.4 billion in 2021 and is expected to reach USD 155.0 billion in 2022.
b.The global biomaterials market is expected to grow at a compound annual growth rate of 15.43% from 2022 to 2030 to reach USD 488.7 billion by 2030.
b.The metallic product segment dominated the biomaterials market with a share of 41.5% in 2021. The wide availability of metallic and advanced materials for tissue fixation and other orthopedic applications is expected to accelerate segment revenue generation.
b.Some key players operating in the biomaterials market include Medtronic plc; Evonik Industries AG; Carpenter Technology Corporation; Berkeley Advanced Biomaterials; Invibio Ltd.; Zimmer Biomet Holdings, Inc.; BASF SE; Covalon Technologies Ltd.; Stryker; Johnson & Johnson; Dentsply Sirona; CoorsTek Inc.;Corbion; and Collagen Matrix, Inc.
b.Key factors that are driving the biomaterials market growth include rising demand as a consequence of accidental injuries & chronic conditions, advances in biomaterials technologies, and expansion in the usage scope of biomaterials.
"The quality of research they have done for us has been excellent."